Abstract
Abstract Plasma cfDNA genotyping has been adopted widely as a tool for genotyping of advanced cancer at diagnosis and after treatment resistance. In addition, cfDNA genomics is a highly quantitative biomarker that could be used dynamically to evaluate the effective of a therapy. Our data point to the potential clinical meaning of changes in plasma mutation levels and support specific best practices regarding the clinical integration of this approach. In addition, these data allow us to envision a number of creative clinical applications for cfDNA-based response assessment. Finally, we must evaluate whether existing cfDNA genotyping technologies are well suited to this application, and whether new techniques must be considered in order to meet the practical requirements of a real-time clinical monitoring test. Citation Format: Geoffrey R. Oxnard. Response in plasma cfDNA as an early marker of treatment effect in advanced cancer [abstract]. In: Proceedings of the AACR Special Conference on Advances in Liquid Biopsies; Jan 13-16, 2020; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2020;26(11_Suppl):Abstract nr IA12.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
